Patent 6916793 was granted and assigned to AntiCancer on July, 2005 by the United States Patent and Trademark Office.
Methods for inhibiting the growth of tumor cells by combination treatment with a selenium-containing prodrug and an enzyme for which it is a substrate are described. The treatment also enhances the effect of anti-tumor agents.